Tivic Health Systems, Inc.TIVCEarnings & Financial Report
Tivic Health Systems, Inc. is a medical technology firm that develops and sells non-invasive, drug-free bioelectronic devices for chronic health condition management. Its flagship product relieves sinus pain and congestion, serving US consumer healthcare markets, with ongoing R&D for new devices targeting other common ailments.
TIVC Q3 FY2025 Key Financial Metrics
Revenue
$146.0K
Gross Profit
$-145.0K
Operating Profit
$-2.5M
Net Profit
$-2.6M
Gross Margin
-99.3%
Operating Margin
-1700.7%
Net Margin
-1778.1%
YoY Growth
15.9%
EPS
$-1.97
Tivic Health Systems, Inc. Q3 FY2025 Financial Summary
Tivic Health Systems, Inc. reported revenue of $146.0K (up 15.9% YoY) for Q3 FY2025, with a net profit of $-2.6M (down 81.4% YoY) (-1778.1% margin). Cost of goods sold was $291.0K, operating expenses totaled $2.3M.
Key Financial Metrics
| Total Revenue | $146.0K |
|---|---|
| Net Profit | $-2.6M |
| Gross Margin | -99.3% |
| Operating Margin | -1700.7% |
| Report Period | Q3 FY2025 |
Tivic Health Systems, Inc. Annual Revenue by Year
Tivic Health Systems, Inc. annual revenue history includes year-by-year totals (for example, 2024 revenue was $780.0K).
Tivic Health Systems, Inc. Quarterly Revenue & Net Profit History
Tivic Health Systems, Inc. results over the last 8 reported quarters, including revenue, net profit and year-over-year growth.
| Quarter | Revenue | Revenue YoY | Net Profit | Net Margin |
|---|---|---|---|---|
| Q3 FY2025 | $146.0K | +15.9% | $-2.6M | -1778.1% |
| Q2 FY2025 | $86.0K | -38.6% | $-1.9M | -2245.3% |
| Q1 FY2025 | $70.0K | -79.0% | $-1.5M | -2145.7% |
| Q4 FY2024 | $180.0K | -49.6% | $-1.5M | -820.6% |
| Q3 FY2024 | $126.0K | -55.3% | $-1.4M | -1135.7% |
| Q2 FY2024 | $140.0K | -13.0% | $-1.3M | -904.3% |
| Q1 FY2024 | $334.0K | -11.2% | $-1.5M | -443.4% |
| Q4 FY2023 | $357.0K | -12.3% | $-2.2M | -628.3% |
Income Statement
| Q4 2023 | Q1 2024 | Q2 2024 | Q3 2024 | Q4 2024 | Q1 2025 | Q2 2025 | Q3 2025 | |
|---|---|---|---|---|---|---|---|---|
| Revenue | $357000 | $334000 | $140000 | $126000 | $180000 | $70000 | $86000 | $146000 |
| YoY Growth | -12.3% | -11.2% | -13.0% | -55.3% | -49.6% | -79.0% | -38.6% | 15.9% |
Balance Sheet
| Q4 2023 | Q1 2024 | Q2 2024 | Q3 2024 | Q4 2024 | Q1 2025 | Q2 2025 | Q3 2025 | |
|---|---|---|---|---|---|---|---|---|
| Assets | $5.2M | $3.3M | $4.8M | $3.4M | $2.8M | $3.8M | $4.5M | $6.2M |
| Liabilities | $1.6M | $1.1M | $591000 | $560000 | $272000 | $741000 | $821000 | $638000 |
| Equity | $3.6M | $2.2M | $4.2M | $2.8M | $2.5M | $3.0M | $3.3M | $3.4M |
Cash Flow
| Q4 2023 | Q1 2024 | Q2 2024 | Q3 2024 | Q4 2024 | Q1 2025 | Q2 2025 | Q3 2025 | |
|---|---|---|---|---|---|---|---|---|
| Operating CF | $-1.8M | $-1.7M | $-1.3M | $-1.4M | $-1.4M | $-889000 | $-1.8M | $-2.0M |